{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:29Z","timestamp":1791215129095,"version":"4.1.0"},"reference-count":110,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T00:00:00Z","timestamp":1319500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Inher Metab Disea"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is an X\u2010linked disorder caused by a deficiency of \u03b1\u2010galactosidase A. This leads to a progressive accumulation of globotriaosylceramide in tissues throughout the body. Cardiac, renal and neurological manifestations are common and life expectancy is significantly reduced relative to the general population. Management of Fabry disease involves the administration of intravenous enzyme replacement therapy (ERT). Two forms \u2013 agalsidase alfa and agalsidase beta \u2013 have been licensed in certain jurisdictions and are generally well tolerated; however, some patients develop antibodies to the infused enzyme, which may impair the efficacy and safety of treatment. Agalsidase alfa and agalsidase beta are produced in different systems; this leads to certain differences in post\u2010translational modification that may affect immunogenicity. Immunoglobulin (Ig) G antibodies have frequently been reported in patients with Fabry disease receiving ERT; IgG responses are reported in a greater proportion of patients receiving agalsidase beta than in patients receiving agalsidase alfa. IgE antibodies are less common than IgG antibodies, and have not been observed in patients receiving agalsidase alfa. However, these data are difficult to interpret due to methodological differences in the assessment of seropositivity, and in the doses of enzyme used. The clinical impact of the development of IgG antibodies to ERT in patients with Fabry disease remains unclear, due to lack of data and to the marked heterogeneity of patients both in terms of disease manifestations and response to therapy. Further studies that examine the development of antibodies in patients with Fabry disease and the potential impact of such antibodies on the outcome of ERT are necessary.<\/jats:p>","DOI":"10.1007\/s10545-011-9400-y","type":"journal-article","created":{"date-parts":[[2011,10,24]],"date-time":"2011-10-24T14:13:24Z","timestamp":1319465604000},"page":"227-243","source":"Crossref","is-referenced-by-count":63,"title":["Fabry disease, enzyme replacement therapy and the significance of antibody responses"],"prefix":"10.1002","volume":"35","author":[{"given":"Patrick B.","family":"Deegan","sequence":"first","affiliation":[{"name":"Department of Medicine Addenbrooke's Hospital Cambridge CB2 2QQ UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1898.tb16317.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.43747.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.51.070182.002531"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568016043356192"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.6.851"},{"key":"e_1_2_8_8_1","unstructured":"BekriS(2006)Importance of glycosylation in enzyme replacement therapy in Fabry disease: perspectives from 5 years of FOS. In:MehtaA BeckM andSunderplassmannG(Eds) Oxford: Oxford PharmaGenesis Ltd.pp45\u201350."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000085709"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152506778520718"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.10.004"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/345309"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318170f868"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196705252762101"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200203000-00003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1385\/MB:28:3:241"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2007.03.008"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011931"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139847.74101.03"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.182257399"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_9.57"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080822"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.01982.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318133fb1b"},{"key":"e_1_2_8_25_1","first-page":"2741","volume-title":"The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2","author":"Desnick RJ","year":"1995"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/318809"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01986897"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00284452"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00189-8"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.01.035"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080816"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1651"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06571.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015511908710"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90665-R"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000178976.62537.6b"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318074c986"},{"key":"e_1_2_8_39_1","first-page":"43","article-title":"Immunological tolerance","volume":"18","author":"Howard JG","year":"1975","journal-title":"Prog Allergy"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/55.2.235"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.104026"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","unstructured":"HuntSV(2009)Perspectives from B cellimmunology: fact and fancy.","DOI":"10.5414\/CPP47086"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3320789"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0896-975"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0305480101"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767030-00007"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.08.003"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2008.00791.x"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwg034"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.063818"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg194"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00924.x"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2009.072116"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181981d82"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9821"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.769"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.750"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/8.4.329"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1994.14.181"},{"key":"e_1_2_8_60_1","unstructured":"MehtaA HughesDA(2008)Anderson\u2010Fabry disease. alpha\u2010galactosidase A deficiency.Includes: classic Fabry disease atypical variants of Fabry disease. GeneReviews."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.07.002"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"issue":"10","key":"e_1_2_8_64_1","first-page":"595","article-title":"Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease","volume":"163","author":"Mills K","year":"2004","journal-title":"Eur J Pediatr"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/1615-9861(200106)1:6<735::AID-PROT735>3.0.CO;2-8"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a124721"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.06.013"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.008"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703509104"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm096"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201044"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004399900075"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K"},{"issue":"5","key":"e_1_2_8_74_1","first-page":"331","article-title":"Antibodies to recombinant human erythropoietin causing pure red cell aplasia","volume":"47","author":"Prabhakar SS","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.11.1522"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1529-1049(02)00049-1"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.5.1402.1402"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2895"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007305299"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67635-0"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088"},{"issue":"3","key":"e_1_2_8_82_1","first-page":"S12","article-title":"Neutralizing antibodies to multiple sclerosis treatments","volume":"10","author":"Rossman HS","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-005-0342-9"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80075-3"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg164"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1092"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80041-0"},{"issue":"2","key":"e_1_2_8_88_1","first-page":"II4","article-title":"Immunogenicity of recombinant human proteins: causes and consequences","volume":"251","author":"Schellekens H","year":"2004","journal-title":"J Neurol"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi152"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006111263"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2007.01.007"},{"key":"e_1_2_8_93_1","unstructured":"SirrsS et al. (2009)Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.Mol Genet Metab."},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000166049.51502.6A"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1086\/504601"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1086\/522236"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.09.007"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-006-0484-8"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000598"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.003"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bb05bb"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1484"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-4415-x"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181a23bec"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00781.x"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1086\/422366"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.09.007"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb02112.x"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3089.2002.02138.x"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300066"}],"container-title":["Journal of Inherited Metabolic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s10545-011-9400-y","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1007\/s10545-011-9400-y","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s10545-011-9400-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:04:51Z","timestamp":1694815491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/s10545-011-9400-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,25]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1007\/s10545-011-9400-y"],"URL":"https:\/\/doi.org\/10.1007\/s10545-011-9400-y","archive":["Portico"],"relation":{},"ISSN":["0141-8955","1573-2665"],"issn-type":[{"value":"0141-8955","type":"print"},{"value":"1573-2665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,25]]}}}